Researchers Share Early Clinical Data on Performance of Quidel MDx Assays | GenomeWeb

Researchers last week provided a glimpse of the clinical performance of a trio of extraction-free molecular assays currently being developed by clinical diagnostics firm Quidel.

Specifically, in a company-sponsored corporate workshop session held in conjunction with the Association for Molecular Pathology meeting in Phoenix, Ariz., the independent investigators presented data from clinical assessments of the Quidel Molecular Group A Strep, AmpliVue Group B/C/G Strep, and Quidel Molecular HSV 1&2/VZV assays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.